The reduced expression of AKT1/2 suggests decreased cell survival, which, coupled with reduced BCL2L1 expression, may contribute to increased apoptosis and lymphopenia in COVID-19 [48, 55]. This evidence concerns the gene BCL2L1 and COVID-19.